緑内障治療薬の世界市場レポート 2025年

緑内障治療薬の市場規模は、今後数年間で力強い成長が見込まれます。2029年には233億8,000万米ドルに成長し、CAGRは7.3%となります。予測期間の成長は、新興市場、償還政策、疾患啓発キャンペーンに起因しています。予測期間の先進包装動向には、技術進歩、イノベーション、遠隔医療、生物製剤と新規治療、徐放性製剤、持続可能性と環境に優しい包装などが含まれます。

緑内障の罹患率は加齢とともに増加する傾向にあり、世界人口の高齢化に伴い、世界中の政府が緑内障やその他の眼疾患に対する認識を高めるための取り組みを開始しています。その一例として、米国疾病予防管理センター（CDC）が開始したビジョンヘルスプログラムは、緑内障を含む眼疾患の予防と目の健康全般の改善に焦点を当てています。さらに、国連総会は、国民皆保険の中で眼科医療サービスを拡大する必要性を強調する決議を行いました。この決議は、特に近視や遠視、緑内障、白内障などの症状による視力低下が持続可能な発展に及ぼす悪影響に対処することを目的としています。このような政府の取り組みにより、緑内障に対する国民の意識が高まり、緑内障治療薬市場の牽引役となることが期待されます。

近視の有病率の上昇は、緑内障治療薬市場の今後の成長を促進すると予想されます。近視は屈折性の眼疾患で、近くのものははっきり見え、遠くのものに焦点を合わせるのが難しいという特徴があります。緑内障治療薬は、患者の近視の進行や屈折の後退を管理し、眼科手術の必要性を減らす効果的な治療法であることが証明されています。例えば、眼科医療を専門とする米国の診療会社NVISION Eye Centersが2022年12月に報告したところによると、米国では2022年に約3,400万人が近視になると予想されています。さらに、オーストリアを拠点とする非営利団体Brien Holden Vision Instituteが2022年5月に発表した報告書によると、2050年までに世界人口の半数が近視になり、予防可能な視力低下に悩む人が50億人に上ると予測されています。その結果、近視の有病率の増加が緑内障治療薬市場の成長促進要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の緑内障治療薬市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の緑内障治療薬市場：成長率分析
• 世界の緑内障治療薬市場の実績：規模と成長、2019～2024年
• 世界の緑内障治療薬市場の予測：規模と成長、2024～2029年、2034年
• 世界の緑内障治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の緑内障治療薬市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院処方薬
• 市販薬
• 世界の緑内障治療薬市場：製品タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• アルファ作動薬
• ベータ遮断薬
• プロスタグランジン類似体
• 併用薬
• その他
• 世界の緑内障治療薬市場：病状別、実績と予測、2019～2024年、2024～2029年、2034年
• 開放隅角緑内障
• 閉塞隅角緑内障
• 正常眼圧緑内障
• 先天性緑内障
• その他
• 世界の緑内障治療薬市場：病院処方薬のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ベータ遮断薬（チモロール）
• プロスタグランジン類似体（ラタノプロスト）
• アルファ作動薬（ブリモニジン）
• 炭酸脱水酵素阻害剤（ドルゾラミド）
• Rhoキナーゼ阻害剤（ネタルスジル）
• 世界の緑内障治療薬市場：市販薬のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 人工涙液
• 眼圧を下げる点眼薬
• ハーブと自然療法

第7章 地域別・国別分析

• 世界の緑内障治療薬市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の緑内障治療薬市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 緑内障治療薬市場：競合情勢
• 緑内障治療薬市場：企業プロファイル
  • Aerie Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Allergan Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Healthcare Pvt. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Merck & Co.
• Genentech Inc.
• Pfizer Inc.
• Bayer AG
• Santen Pharmaceuticals Company Ltd.
• Regeneron Pharmaceuticals Inc.
• Valeant Pharmaceuticals International Inc.
• F. Hoffmann-La Roche Ltd.
• Hoya Corporation
• Bausch+Lomb Inc.
• Fera Pharmaceuticals LLC
• Thea Pharma Inc.
• Alcon AG
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 緑内障治療薬市場2029：新たな機会を提供する国
• 緑内障治療薬市場2029：新たな機会を提供するセグメント
• 緑内障治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Antiglaucoma drugs are medications employed in the treatment and prevention of glaucoma, a vision-related condition characterized by progressive, irreversible optic nerve damage leading to vision loss.

The primary categories of antiglaucoma drugs include alpha agonists, beta-blockers, prostaglandin analogs, combined medications, and other related products. Alpha-adrenergic agonists are a class of sympathomimetic drugs that selectively activate alpha-adrenergic receptors. These antiglaucoma products are available through both hospital prescriptions and over-the-counter channels and are utilized to manage various types of glaucoma, including open-angle glaucoma, angle-closure glaucoma, normal-tension glaucoma, congenital glaucoma, and other forms of the condition.

The antiglaucoma drug market research report is one of a series of new reports from The Business Research Company that provides antiglaucoma drug market statistics, including antiglaucoma drug industry global market size, regional shares, competitors with an antiglaucoma drug market share, detailed antiglaucoma drug market segments, market trends and opportunities, and any further data you may need to thrive in the antiglaucoma drug industry. This antiglaucoma drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antiglaucoma drugs market size has grown strongly in recent years. It will grow from $16.33 billion in 2024 to $17.63 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to aging population, increasing awareness, growing healthcare expenditure, regulatory approvals.

The antiglaucoma drugs market size is expected to see strong growth in the next few years. It will grow to $23.38 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to emerging markets, reimbursement policies, disease awareness campaigns. Major trends in the forecast period include technological advancements, innovation, telemedicine, biologics and novel therapies, sustained-release formulations, sustainability and eco-friendly packaging.

The incidence of glaucoma tends to increase with age, and as the global population ages, governments around the world are launching initiatives to raise awareness about glaucoma and other eye disorders. An example of such an initiative is the Vision Health program initiated by the Centers for Disease Control and Prevention (CDC) in the United States, which focuses on preventing eye disorders, including glaucoma, and improving overall eye health. Furthermore, the United Nations General Assembly passed a resolution emphasizing the need to expand eye care services within universal health coverage. The resolution aimed to address the adverse impacts of vision loss on sustainable development, particularly due to conditions like short and farsightedness, glaucoma, and cataracts. These government initiatives are expected to increase awareness among the public about glaucoma, which, in turn, will drive the market for antiglaucoma drugs.

The rising prevalence of myopia is expected to drive the growth of the antiglaucoma drugs market in the future. Myopia is a refractive eye condition characterized by clear vision of nearby objects but difficulty focusing on distant objects. Antiglaucoma drugs have proven to be an effective therapy for managing myopia progression and refractive regression in patients, reducing the need for ophthalmic surgeries. For instance, in December 2022, as reported by NVISION Eye Centers, a US-based medical practice company specializing in eye care, approximately 34 million people in the United States were expected to have myopia in 2022. Furthermore, a May 2022 report from the Brien Holden Vision Institute, an Austria-based nonprofit organization, projected that by 2050, half of the global population will experience myopia, with an estimated 5 billion individuals suffering from preventable vision loss. As a result, the increasing prevalence of myopia is a significant driver of growth in the antiglaucoma drugs market.

Companies in the antiglaucoma drugs market are actively developing combination therapies for the treatment of glaucoma, as these therapies have shown the ability to effectively lower intraocular pressure in glaucoma patients. Many of these combination therapies are formulated as fixed-dose drugs, offering patients the convenience of consuming multiple active ingredients in a single formulation. For instance, Alcon introduced Simbrinza, a fixed combination drug that combines Brinzolamide and Brimonidine. This product is designed to help patients reduce the need for multiple individual drugs in the treatment of glaucoma. Other examples include Rockland, a combination of a rho kinase inhibitor and a prostaglandin analog, Combigan, which combines beta blockers and alpha agonists, and Cosopt, a combination of beta-blockers and carbonic anhydrase inhibitors. These combination therapies provide glaucoma patients with effective treatment options that streamline their medication regimens.

Major companies in the antiglaucoma drug market are dedicated to innovation, developing new products to better serve their customers. One such innovative product is OMLONTI (Omidenepag Isopropyl Ophthalmic Solution), which is administered as an antiglaucoma eye drop treatment, particularly effective for open-angle glaucoma. For instance, in September 2022, Santen Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, collaborated with UBE Corporation, a Japan-based chemical company, to launch OMLONTI (Omidenepag Isopropyl Ophthalmic Solution), which received approval from the US Food and Drug Administration (FDA). OMLONTI is in the form of eye drops and is employed for reducing elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. It is unique in its pharmacological action, as it is a selective prostaglandin EP2 receptor agonist, making it the only product with this distinct mechanism of action in the market. This kind of innovation demonstrates the commitment of these companies to delivering improved treatment options in the antiglaucoma drug market.

To obtain approval from the United States Food and Drug Administration (USFDA) for an antiglaucoma drug, the drug needs to demonstrate comparable intraocular pressure (IOP) lowering efficacy and a favorable benefit-to-risk ratio in comparison to established benchmark drugs used for the treatment of glaucoma. An example of such an approval is Rhopressa (netarsudil) Ophthalmic Solution, developed by Aerie Pharmaceuticals Inc. This drug received US FDA approval based on its ability to effectively lower IOP when compared to the benchmarked drugs already available for the treatment of glaucoma in the market. This stringent evaluation ensures that new antiglaucoma drugs meet the required standards for safety and efficacy.

Major companies operating in the antiglaucoma drugs market include Aerie Pharmaceuticals Inc., Allergan Inc., Novartis AG, Abbott Healthcare Pvt. Ltd., Johnson & Johnson, Merck & Co., Genentech Inc., Pfizer Inc., Bayer AG, Santen Pharmaceuticals Company Ltd., Regeneron Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., F. Hoffmann-La Roche Ltd., Hoya Corporation, Bausch + Lomb Inc., Fera Pharmaceuticals LLC, Thea Pharma Inc., Alcon AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Akorn Inc., Mylan Pharmaceuticals Pvt. Ltd., Apotex Inc., Lupin Pharmaceuticals Inc., Wockhardt Ltd., Zydus Pharmaceuticals Inc., Cooper Laboratories Inc., Cooper Pharma Ltd., Rafarm SA, Altaire Pharmaceuticals Inc.

North America was the largest region in the antiglaucoma drugs market in 2024. Middle East is expected to be the fastest-growing region in the antiglaucoma drugs market during the forecast period. The regions covered in the antiglaucoma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the antiglaucoma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antiglaucoma drug market consists of sales of dipivefrin, epinephrine, and apraclonidine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antiglaucoma Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antiglaucoma drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antiglaucoma drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antiglaucoma drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Hospital Prescription Drugs; Over-The Counter Drugs
• 2) By Product Type: Alpha Agonist; Beta Blockers; Prostaglandin Analogs; Combined Medication; Other Types
• 3) By Disease Condition Type: Open-Angle Glaucoma; Angle-Closure Glaucoma; Normal-Tension Glaucoma; Congenital Glaucoma; Other Types Of Glaucoma
• Subsegments:
• 1) By Hospital Prescription Drugs: Beta-Blockers (Timolol); Prostaglandin Analogs (Latanoprost); Alpha Agonists (Brimonidine); Carbonic Anhydrase Inhibitors (Dorzolamide); Rho Kinase Inhibitors (Netarsudil)
• 2) By Over-The-Counter Drugs: Artificial Tears; Eye Drops For IOP Reduction; Herbal And Natural Remedies
• Companies Mentioned: Aerie Pharmaceuticals Inc.; Allergan Inc.; Novartis AG; Abbott Healthcare Pvt. Ltd.; Johnson & Johnson
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Antiglaucoma Drugs Market Characteristics

3. Antiglaucoma Drugs Market Trends And Strategies

4. Antiglaucoma Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Antiglaucoma Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Antiglaucoma Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Antiglaucoma Drugs Market Growth Rate Analysis
• 5.4. Global Antiglaucoma Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Antiglaucoma Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Antiglaucoma Drugs Total Addressable Market (TAM)

6. Antiglaucoma Drugs Market Segmentation

• 6.1. Global Antiglaucoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Prescription Drugs
• Over-The-Counter Drugs
• 6.2. Global Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alpha Agonist
• Beta Blockers
• Prostaglandin Analogs
• Combined Medication
• Other Types
• 6.3. Global Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Open-Angle Glaucoma
• Angle-Closure Glaucoma
• Normal-Tension Glaucoma
• Congenital Glaucoma
• Other Types Of Glaucoma
• 6.4. Global Antiglaucoma Drugs Market, Sub-Segmentation Of Hospital Prescription Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Beta-Blockers (Timolol)
• Prostaglandin Analogs (Latanoprost)
• Alpha Agonists (Brimonidine)
• Carbonic Anhydrase Inhibitors (Dorzolamide)
• Rho Kinase Inhibitors (Netarsudil)
• 6.5. Global Antiglaucoma Drugs Market, Sub-Segmentation Of Over-The-Counter Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Artificial Tears
• Eye Drops For IOP Reduction
• Herbal And Natural Remedies

7. Antiglaucoma Drugs Market Regional And Country Analysis

• 7.1. Global Antiglaucoma Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Antiglaucoma Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Antiglaucoma Drugs Market

• 8.1. Asia-Pacific Antiglaucoma Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Antiglaucoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Antiglaucoma Drugs Market

• 9.1. China Antiglaucoma Drugs Market Overview
• 9.2. China Antiglaucoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Antiglaucoma Drugs Market

• 10.1. India Antiglaucoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Antiglaucoma Drugs Market

• 11.1. Japan Antiglaucoma Drugs Market Overview
• 11.2. Japan Antiglaucoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Antiglaucoma Drugs Market

• 12.1. Australia Antiglaucoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Antiglaucoma Drugs Market

• 13.1. Indonesia Antiglaucoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Antiglaucoma Drugs Market

• 14.1. South Korea Antiglaucoma Drugs Market Overview
• 14.2. South Korea Antiglaucoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Antiglaucoma Drugs Market

• 15.1. Western Europe Antiglaucoma Drugs Market Overview
• 15.2. Western Europe Antiglaucoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Antiglaucoma Drugs Market

• 16.1. UK Antiglaucoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Antiglaucoma Drugs Market

• 17.1. Germany Antiglaucoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Antiglaucoma Drugs Market

• 18.1. France Antiglaucoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Antiglaucoma Drugs Market

• 19.1. Italy Antiglaucoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Antiglaucoma Drugs Market

• 20.1. Spain Antiglaucoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Antiglaucoma Drugs Market

• 21.1. Eastern Europe Antiglaucoma Drugs Market Overview
• 21.2. Eastern Europe Antiglaucoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Antiglaucoma Drugs Market

• 22.1. Russia Antiglaucoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Antiglaucoma Drugs Market

• 23.1. North America Antiglaucoma Drugs Market Overview
• 23.2. North America Antiglaucoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Antiglaucoma Drugs Market

• 24.1. USA Antiglaucoma Drugs Market Overview
• 24.2. USA Antiglaucoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Antiglaucoma Drugs Market

• 25.1. Canada Antiglaucoma Drugs Market Overview
• 25.2. Canada Antiglaucoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Antiglaucoma Drugs Market

• 26.1. South America Antiglaucoma Drugs Market Overview
• 26.2. South America Antiglaucoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Antiglaucoma Drugs Market

• 27.1. Brazil Antiglaucoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Antiglaucoma Drugs Market

• 28.1. Middle East Antiglaucoma Drugs Market Overview
• 28.2. Middle East Antiglaucoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Antiglaucoma Drugs Market

• 29.1. Africa Antiglaucoma Drugs Market Overview
• 29.2. Africa Antiglaucoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Antiglaucoma Drugs Market Competitive Landscape And Company Profiles

• 30.1. Antiglaucoma Drugs Market Competitive Landscape
• 30.2. Antiglaucoma Drugs Market Company Profiles
  • 30.2.1. Aerie Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Allergan Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbott Healthcare Pvt. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

31. Antiglaucoma Drugs Market Other Major And Innovative Companies

• 31.1. Merck & Co.
• 31.2. Genentech Inc.
• 31.3. Pfizer Inc.
• 31.4. Bayer AG
• 31.5. Santen Pharmaceuticals Company Ltd.
• 31.6. Regeneron Pharmaceuticals Inc.
• 31.7. Valeant Pharmaceuticals International Inc.
• 31.8. F. Hoffmann-La Roche Ltd.
• 31.9. Hoya Corporation
• 31.10. Bausch + Lomb Inc.
• 31.11. Fera Pharmaceuticals LLC
• 31.12. Thea Pharma Inc.
• 31.13. Alcon AG
• 31.14. Teva Pharmaceutical Industries Ltd.
• 31.15. Sun Pharmaceutical Industries Ltd.

32. Global Antiglaucoma Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antiglaucoma Drugs Market

34. Recent Developments In The Antiglaucoma Drugs Market

35. Antiglaucoma Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Antiglaucoma Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Antiglaucoma Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Antiglaucoma Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer